Trial Profile

A Randomized Open-label Dose-ranging, Multi-center Trial to Assess the Safety and Efficacy of NKPL66 (CaPre) in the Treatment of Mild-to-moderate Hypertriglyceridemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Oct 2024 According to an Acasti Pharma media release, company name Acasti Pharma changed to Grace Therapeutics, Inc.
14 Aug 2017 According to an Acasti Pharma media release, select data from this and other studies (TRIFECTA, PMRI2016-4010 and CAP13-101) will be submitted for publication in a peer-reviewed journal.
14 Aug 2017 Results from this study were included in an oral presentation at the International Academy of Cardiology Annual Scientific Sessions 22nd World Congress on Heart Disease (WCHD), according to an Acasti Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com